QV EQUITIES (ASX: QVE) QUARTERLY REPORT




31 MARCH 2024

QVE Equities (QVE) is a Listed Investment Company (LIC) managed by Australian equities asset manager IML. It invests in high-quality, good value companies listed on the ASX outside the top 20, aiming to provide a rate of return which exceeds the return of its benchmark on a rolling 5+ year basis. QVE aims to deliver a consistent quarterly income stream for shareholders, while also growing capital gradually over time.

QVE COMPANY NEWS

The formal evaluation of strategic options for QVE (Strategic Review) which was announced to the market on 31 January 2024 has been concluded. QVE announced on 12 March 2024 jointly with WAM Leaders Limited (ASX: WLE) that the parties have entered into a Scheme Implementation Agreement (SIA) to merge the two entities through a Scheme of Arrangement (Proposed Transaction). Per the announcement, QVE shareholders will be given the opportunity to vote on the Proposed Transaction and detailed information relating to the Proposed Transaction will be provided to QVE shareholders in due course. Read the full announcement here.

QVE HISTORICAL DIVIDENDS (FULLY FRANKED)



Total fully franked dividends paid since inception

40.3 CENTS PER SHARE

Source: QV Equities. Past performance is not a reliable indicator of future performance. As a result, past dividends are not indicative of future dividends.

| COMPANY SNAPSHOT | |
|-------------------------------|--|
| ASX code | QVE |
| NTA ¹ before tax | 1.06 |
| NTA ¹ after tax | 1.09 |
| Dividend frequency | Quarterly |
| Yield ² | 5.23% |
| Grossed up yield ³ | 7.47% |
| FY23 dividends ⁴ | 5.2 cps |
| Management fee | 0.90% p.a. of the NAV up to \$150m 0.75% p.a. over \$150m |
| Performance fee | Nil |
| Shares on issue | 227M |
| Portfolio Managers | Simon Conn Marc Whittaker |
| Listing date | 22 August 2014 |

SHAREHOLDER BENEFITS

What should you expect when you invest with QVE?

Consistent income, growing over time*

QVE aims to pay quarterly, fully-franked
dividends, giving Australian investors
additional income through tax offsets or

refunds. Portfolio diversification

QVE invests outside the ASX Top20, providing diversification benefits for investors who hold shares in the largest Australian companies.

Experienced Board and Investment Manager with a 25-year track record.

Past performance is not a reliable indicator of future performance. As a result, past dividends are not indicative of future dividends.

*Refers to dividend income. See QVE historical dividends chart above.

1. The before and after tax NTA numbers relate to the provision for tax on net profit in addition to deferred tax on the unrealised gains/losses in the Company's investment portfolio. Under current accounting standards, the Company is required to provide for tax on any gains/losses that might arise on such a theoretical disposal, after utilisation of brought forward losses. All figures are unaudited and approximate. 2. Trailing 12 month yield on month end share price 3. Includes franking credits 4. Dividends paid for the financial year 2023 reporting period. Past performance is not a reliable indicator of future performance.

QV EQUITIES (ASX: QVE) QUARTERLY REPORT



UPDATE FROM THE INVESTMENT MANAGER

MARKET CONTEXT

- The rally in global markets continued over Q1 2024 as investors grew increasingly comfortable that global interest rates had peaked, with expectations growing that cash rates will be reduced later this year. The AI thematic also boosted returns, as did a resurgent Japanese market where the Bank of Japan raised interest rates for the first time in 17 years.
- The Nikkei was the strongest global market, up +21.5% for the quarter, as investors re-allocated from a troubled China. The MSCI, S&P 500 and Nasdaq were also strong, up around 10%, with Europe's Stoxx 50 up +12.9%. Australian markets performed well but lagged their global peers, with the ASX 300 up +5.4%. All ex-20 sectors climbed with Technology the standout, up +23.6% due to takeover activity and in sympathy with the Nasdaq.

PORTFOLIO COMMENTARY

- The **QVE Portfolio** had a strong quarter, up +5.9%, however lagging the benchmark's gain of +8.3% mainly due to our caution towards the richly-priced technology sector. Given the strong gains recorded by many stocks we have been trimming company positions to lock in gains, and will prudently redeploy cash given the pending SIA vote.
- Many of the portfolio's stocks performed well over the quarter including recent additions SG Fleet and Sigma Healthcare, while long-term holdings Virgin UK, Mayne Pharma, Integral Diagnostics, SkyCity, Orica and Aurizon also performed strongly. Sigma Healthcare rose as investor knowledge grew regarding the merger with Chemist Warehouse (CW), with the result late in the quarter highlighting the strength of the CW performance while Virgin Money UK soared after announcing it would be acquired by Nationwide, the UK's largest building society.
- Orica (ORI), the leading global explosives company, was up +12.4% for the quarter following a positive trading update and the acquisition of a leading sodium cyanide manufacturer, Cyanco for US\$640m. To fund the acquisition Orica raised A\$400m in an institutional placement at \$15.84, in which QVE participated. Cyanco complements Orica's existing sodium cyanide business and makes Orica the clear global leader, with significant synergies to be derived from combining these businesses.
- Aurizon (AZJ), Australia's largest rail freight operator, was up +7.8% for the quarter following a solid H1'24 result with all divisions delivering improved results. Coal volumes recovered from last year's weather induced softness with NSW and QLD year-on-year revenues up +9% for the quarter, while the regulated network division gained on the back of a higher allowed rate of return following the increase in bond rates. The Bulk division also delivered an improved result on the back of new contracts and a volume recovery by customers. Going forward the recently won contract with Team Global Express (TGE) is likely to further bolster the bulk, non-coal haulage business.
- Sonic Healthcare (SHL), the global pathology leader, fell -7.0% over the quarter largely due to a non-operational issue in the H1'24 result with a higher-than-expected interest expense leading to a downgrade in market forecasts. Sonic continued to redeploy its cash generated during the Covid period acquiring a Swiss lab group, 'Dr Risch', for c\$200m, enhancing its existing operational footprint in Switzerland. We believe Sonic's competitive position across key markets has it well placed for long-term growth, as many smaller competitors struggle post Covid.
- During the quarter we trimmed our positions in A2B Australia, Sigma Healthcare, Metcash, Medibank, IAG, Aurizon and Suncorp and exited Resmed and Regis Healthcare locking in gains while increasing our positions in APA, Origin, Sonic Healthcare, Integral Diagnostics and SG Fleet at what we believe to be attractive valuations.

OUTLOOK

- We expect market volatility to persist and meaningful revenue growth to continue to be hard for companies to generate in 2024 as cost pressures remain a challenge for businesses and cost-of-living pressures weigh on the consumer.
- We continue to focus on well-established companies with strong competitive advantages and recurring earnings that are reasonably priced and likely to perform well in a range of economic conditions, while we continue to actively look for new opportunities.


| PERFORMANCE | 1 MONTH | 3 MONTHS | 1 YEAR | 3 YEARS^ | 5 YEARS^ | SINCE LISTING [^] 22 AUG 2014 |
|-------------------|---------|----------|--------|----------|----------|---|
| QVE NTA (pre-tax) | +3.9% | +5.9% | +11.1% | +6.5% | +4.7% | +6.0% |
| Benchmark** | +4.3% | +8.3% | +15.3% | +8.0% | +8.2% | +9.1% |

[^] Performance per annum. ** The benchmark is the S&P/ASX 300 Ex20 Accumulation. The above returns are after fees, assume all declared dividends are reinvested, and exclude tax paid from pre-tax NTA. Past performance is not a reliable indicator of future performance.

QV EQUITIES QUARTERLY REPORT



PORTFOLIO DATA*



| TOP 10 HOLDINGS | ASX CODE | WEIGHT |
|--------------------------|----------|--------|
| Aurizon | AZJ | 4.9% |
| APA | APA | 4.2% |
| Sonic Healthcare | SHL | 4.1% |
| Amcor PLC | AMC | 3.7% |
| Orica | ORI | 3.7% |
| Suncorp | SUN | 2.8% |
| Skycity Entertainment | SKC | 2.7% |
| Charter Hall Retail REIT | CQR | 2.5% |
| Brambles | BXB | 2.3% |
| Santos | STO | 2.2% |

| PORTFOLIO INFORMATION | | | |
|-----------------------|----------------------------------|--|--|
| Benchmark | S&P/ASX 300 Ex20 Accumulation | | |
| No. of stocks | 47 | | |
| Cash weight | 21% | | |

Important note: Shares of Listed Investment Companies (including QVE) can trade at a discount or a premium to the Net Tangible Assets (NTA) per share of the Company. The share price of any company is based on demand for the shares, compared to the supply of the shares.

Release authorised by Company Secretary, Zac Azzi.



qvequities.com



info@qvequities.com



1300 551 132

Level 24, 25 Bligh Street, Sydney NSW 2000 | PO Box H104, Australia Square, Sydney NSW 1215 | ACN 169 154 858 Shareholder Services (Link Market Services): 1800 868 464

Please direct distribution enquiries to your representative from Natixis Investment Managers

Natixis Investment Managers Australia Pty Limited AFSL 246830 has prepared and distributed the information in this announcement, under an arrangement with Investors Mutual Limited AFSL 229988, as the Investment manager for, and on behalf of, QV Equities Limited ACN 169 154 858 (QVE). This announcement has been prepared for the purposes of providing general information only and does not constitute an offer, solicitation or recommendation with respect to the purchase or sale of any securities in QVE nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this announcement in making an investment decision but must make their own assessment of QVE and conduct their own investigations and analysis. Sharemarkets can move up and down and this may adversely impact your investment return. Past performance is not a reliable indicator of future performance.

^{*} Numbers may not add up to 100% due to rounding.